Honesti Basyir, president director at Kimia Farma, explains the transition towards digitalization in the healthcare industry and his plans to take Kimia Farma from the top six to the top three in the Indonesian pharmaceutical industry by 2019.
Mr. Honesti, you were appointed president director of Kimia Farma in April 2017. After having spent the majority of your career in telecommunications, how do you believe your background will help you succeed in Kimia Farma?
"Even though the market is growing in terms of volume, this is not exactly reflected in the value, primarily due to the implementation of the Indonesian Universal Healthcare Coverage (JKN), which is highly driven by cost containment but also exposed to the fluctuation of the exchange rate"
